Viskase Holdings, Inc.

VISK ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $42.6M $46.9M $47.0M $47.0M $47.6M $48.1M $5.4M $6.5M
Accounts Receivable — — — — — — — —
Inventory — — — — — — — —
Total Current Assets $42.8M $47.2M $47.3M $47.4M $47.8M $48.2M $6.0M $14.5M
Property, Plant & Equipment — — — — — — — —
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $42.8M $47.2M $47.7M $47.6M $47.8M $48.2M $6.5M $15.5M
Liabilities
Accounts Payable $331.0K $331.0K $331.0K $331.0K $331.0K $302.0K $324.0K $439.0K
Total Current Liabilities $731.0K $1.7M $1.7M $1.7M $403.0K $412.0K $423.0K $517.0K
Long-Term Debt — — — — — — — —
Total Liabilities $45.3M $44.2M $51.2M $44.2M $42.9M $40.9M $423.0K $517.0K
Stockholders' Equity
Retained Earnings $-73.3M $-69.9M $-70.7M $-72.0M $-71.9M $-71.4M $-70.1M $-69.1M
Total Stockholders' Equity $-2.5M $3.0M $-3.5M $3.4M $4.9M $7.4M $6.1M $15.0M
← Newer Page 1 of 2 Older →